{"id":"anti-pseudomonal-penicillin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Diarrhea"},{"rate":"3-10","effect":"Nausea"},{"rate":"2-8","effect":"Vomiting"},{"rate":"2-5","effect":"Rash"},{"rate":"0.5-2","effect":"Allergic reactions (including anaphylaxis)"},{"rate":"1-3","effect":"Clostridium difficile-associated diarrhea"},{"rate":"2-5","effect":"Phlebitis at injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These beta-lactam antibiotics work by disrupting bacterial cell wall integrity through inhibition of peptidoglycan cross-linking. Anti-pseudomonal penicillins (such as piperacillin and ticarcillin) have broader gram-negative coverage and greater activity against Pseudomonas aeruginosa than aminopenicillins, making them suitable for serious infections caused by this opportunistic pathogen. They are often combined with beta-lactamase inhibitors to extend coverage against beta-lactamase-producing organisms.","oneSentence":"Anti-pseudomonal penicillins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing cross-linking of peptidoglycan, with enhanced activity against Pseudomonas aeruginosa compared to standard penicillins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:30.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious infections caused by Pseudomonas aeruginosa and other gram-negative bacteria"},{"name":"Hospital-acquired pneumonia"},{"name":"Febrile neutropenia in immunocompromised patients"},{"name":"Intra-abdominal infections"}]},"trialDetails":[{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":"Acute Kidney Injury","enrollment":750},{"nctId":"NCT06977347","phase":"NA","title":"Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea","status":"NOT_YET_RECRUITING","sponsor":"CHOSEOK YOON","startDate":"2025-06-15","conditions":"Severe Community-acquired Pneumonia (sCAP)","enrollment":100},{"nctId":"NCT05094154","phase":"PHASE4","title":"Effect of Antibiotic Choice On ReNal Outcomes (ACORN)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-11-10","conditions":"Sepsis, AKI, Neurotoxicity","enrollment":2634}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"anti-pseudomonal penicillin","genericName":"anti-pseudomonal penicillin","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-pseudomonal penicillins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing cross-linking of peptidoglycan, with enhanced activity against Pseudomonas aeruginosa compared to standard penicillins. Used for Serious infections caused by Pseudomonas aeruginosa and other gram-negative bacteria, Hospital-acquired pneumonia, Febrile neutropenia in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}